Innovestor | Investment Thesis & Preferences

01Investment Thesis

Backing good ideas with capital and competence - combining financial backing with active ownership, extensive networks and experienced operating support to be founders' first VC check from concept through Series A.

02Investment Team

WL

Wilhelm Lindholm

Group CEO

TÄ

Tommi Äijälä

Group Chair

PL

Petri Laine

Venture Partner

PM

Piia Maaranen

Partner, Technology Fund

MS

Myron Seto

Partner, Technology Fund

MR

Mikko Rautiainen

Investment Manager, Technology Fund

LK

Lauri Karjalainen

Investment Manager, Technology Fund

MK

Marko Kuisma

Partner, Life Science Fund

MK

Milla Koistinaho

Partner, Life Science Fund

PS

Pekka Simula

Partner, Life Science Fund

SK

Sara Kangaspeska

Investment Director, Life Science Fund

EC

Emilia Carlqvist

Analyst, Life Science Fund

03F4 Research Brief

Innovestor Research

Investment Thesis

Innovestor is a Helsinki-based investment group founded in 2014, built around the idea of "Making Good Money" - backing businesses that create the greatest impact alongside strong financial returns. What began as an online co-investment platform has grown into one of the most active Nordic venture capital firms, now spanning six venture capital funds, a corporate venturing practice, a real estate business, and an energy storage business. Across all of these lines, Innovestor positions itself as a long-term partner to founders and asset owners rather than a single-round capital provider, emphasizing active ownership, deep sector networks, and hands-on operating support.

Stage Focus

Innovestor's venture capital arm targets early-stage companies and explicitly positions itself as the "first VC check" for entrepreneurs raising external capital. The Technology Fund invests from Seed through Series A. The Life Science Fund invests from Pre-Seed through Series A. The Angel CoFund complements both by co-investing alongside angel investor syndicates at the earliest stages, and the PALO Accelerator Program supports pre-seed sustainable technology startups.

Check Size

Technology Fund: initial tickets of EUR 250K to EUR 1M
Life Science Fund: initial tickets of EUR 250K to EUR 3M
Angel CoFund: smaller co-investment checks alongside syndicates of angel investors, with active follow-on participation

Lead Tendency

Not explicitly disclosed on the website. Public deal coverage (e.g., the Actithera Series A) shows Innovestor participating alongside larger co-lead investors such as M Ventures, Sofinnova Partners, and Hadean Ventures rather than leading, though the firm's own "first VC check" positioning suggests it does lead at the earliest (Angel CoFund and pre-seed) stages. Treated as unknown pending more evidence.

Recent Activity

Innovestor has been actively deploying through 2025 and into 2026:

January 2026: Reported 74 total investments across the group in 2025, alongside a real estate exit that included integrated battery systems.
August 2025: The Life Science Fund made its 14th investment, co-investing in Actithera's USD 75.5M Series A alongside M Ventures, Hadean Ventures, Sofinnova Partners, 4BIO Capital, Bioqube Ventures, Investinor, Surveyor Capital, and Arkin Bio Ventures II.
June 2025: Angel CoFund closed a busy first half with 9 new investments and 5 follow-on investments.
November 2025: Innovestor completed the sale of four Finnish retail assets to Prisma Properties, an exit on the real estate side of the business.
February 2026: Announced a partnership with Grid.vc to build a next-generation fund together.
August 2026: Angel CoFund reported it had already exceeded the prior full year's investment pace within the first eight months of 2026, signaling continued acceleration.

Portfolio Highlights

Innovestor's venture portfolio spans well over 100 companies across technology and life science, including 73Health (remote medical examination SaaS), 7Signal Solutions (WiFi performance management), 9Solutions (digital health platform), Aatos (digital commerce), Abacus Diagnostica (diagnostics), Adeu AI (AI-powered legal time tracking), AegisNet (drone protection/defense tech), Aispeco (geospatial data collection), Alex Therapeutics (digital CBT therapeutics), Amertate (hybrid wind turbines), Amplifiles (AI property photo-to-video), Aplagon and Aurealis Pharma and Aranda Pharma (therapeutics), Arilyn (augmented reality as a service), and ArcDia International and BBS-Bioactive Bone Substitutes (medtech). The firm has also published research noting emerging trends across its growing AI portfolio, suggesting an increasing share of AI-native investments.

Team

Wilhelm Lindholm - Group CEO
Tommi Aijala - Group Chair
Petri Laine - Venture Partner (spans Technology and Life Science funds)
Piia Maaranen - Partner, Technology Fund
Myron Seto - Partner, Technology Fund
Mikko Rautiainen - Investment Manager, Technology Fund
Lauri Karjalainen - Investment Manager, Technology Fund
Marko Kuisma - Partner, Life Science Fund
Milla Koistinaho - Partner, Life Science Fund
Pekka Simula - Partner, Life Science Fund
Sara Kangaspeska - Investment Director, Life Science Fund
Emilia Carlqvist - Analyst, Life Science Fund

Decision Process

Both the Technology Fund and Life Science Fund are run by multi-partner teams (three partners plus investment managers/directors on each), consistent with a partnership-style decision process rather than a solo GP model.

Founder Preferences

Innovestor backs technical and scientific founders building breakthrough innovations aligned with global megatrends: enterprise/B2B and industrial technology on the Technology Fund side, and biotech/digital health addressing unmet medical needs on the Life Science Fund side. The firm emphasizes companies with international scaling potential rather than purely domestic Finnish plays.

Geographic Focus

Innovestor's venture funds are focused on the Nordics and Baltics region, headquartered in Helsinki, Finland, with a stated goal of giving Nordic and Baltic founders access to European growth capital and networks.